Sarepta Therapeutics (SRPT) Tops Q2 EPS by 92c

Sarepta Therapeutics (NASDAQ: SRPT) reported Q2 EPS of ($0.85), $0.92 better than the analyst estimate of ($1.77). Revenue for the quarter came in at $261.2 million versus the consensus estimate of $259.79 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• TJX stock drops as profit outlook falls short of analyst estimates
• TOYO Co., Ltd (TOYO) Misses Q2 EPS by 24c
• Baidu (BIDU) PT Lowered to $150 at Benchmark on Near-Term Margin Concerns